Evidence map›Paper›PMID 36324747›Full record

ArticleFrontiers in cardiovascular medicine2022

SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19.

Margo Daems, Laurens Liesenborghs, Robbert Boudewijns, Steven J Simmonds, Sirima Kraisin, Jore Van Wauwe, Ilona Cuijpers, Jana Raman, Nadèche Geuens, Tina Van Buyten and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. COVID-19, Myocarditis and Pericarditis.Circulation research · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Margo DaemsCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Laurens LiesenborghsCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Robbert BoudewijnsLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Steven J SimmondsCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Sirima KraisinCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Jore Van WauweCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Ilona CuijpersCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Jana RamanCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Nadèche GeuensCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Tina Van BuytenLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Marleen LoxCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Peter VerhammeCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Sophie Van LinthoutVirchow Clinic, Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - University Medicine Berlin, Berlin, Germany.
Kimberly MartinodCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Stephane HeymansCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Carsten TschöpeVirchow Clinic, Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité - University Medicine Berlin, Berlin, Germany.
Johan NeytsLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Elizabeth A V JonesCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
KU Leuven · BEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEGerman Centre for Cardiovascular Research · DEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recovered COVID-19 patients often display cardiac dysfunction, even after a mild infection. Most current histological results come from patients that are hospitalized and therefore represent more severe outcomes than most COVID-19 patients face. To overcome this limitation, we investigated the cardiac effects of SARS-CoV-2 infection in a hamster model. SARS-CoV-2 infected hamsters developed diastolic dysfunction after recovering from COVID-19. Histologically, increased cardiomyocyte size was present at the peak of viral load and remained at all time points investigated. As this increase is too rapid for hypertrophic remodeling, we found instead that the heart was oedemic. Moreover, cardiomyocyte swelling is associated with the presence of ischemia. Fibrin-rich microthrombi and pericyte loss were observed at the peak of viral load, resulting in increased HIF1α in cardiomyocytes. Surprisingly, SARS-CoV-2 infection inhibited the translocation of HIF1α to the nucleus both in hamster hearts, in cultured cardiomyocytes, as well as in an epithelial cell line. We propose that the observed diastolic dysfunction is the consequence of cardiac oedema, downstream of microvascular cardiac ischemia. Additionally, our data suggest that inhibition of HIF1α translocation could contribute to an exaggerated response upon SARS-CoV-2 infection.

Indexed as

cardiac oedemaCOVID-19diastolic dysfunctionHIF1αhypoxiapericyte loss

Identifiers

PMID36324747
PMCPMC9618878
OpenAlexW4306385427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.